We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Adrenaline Injections to Children Born at Elective CS

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: May 8, 2006
Last Update Posted: June 28, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Hvidovre University Hospital
Children born after elective C-section have a greater risk of respiratory problems and hypoglycemia - most likely due to a lower concentration of stress hormones compared to children born vaginally. Hypothesis: can we eliminate or reduce the risk of respiratory distress and hypoglycaemia by administrating adrenaline to the newborn.

Condition Intervention
Respiratory Distress Hypoglycemia Drug: Adrenaline

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Can the Risk of RD and Hypoglycemia in Children Born at Elective CS be Reduced by Injection of Adrenaline

Resource links provided by NLM:

Further study details as provided by Hvidovre University Hospital:

Primary Outcome Measures:
  • respiratory distress
  • hypoglycemia

Enrollment: 270
Study Start Date: June 2006
Study Completion Date: June 2007

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 1 Day   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • All children born at elective section with gestational age more than 37 + 0

Exclusion Criteria:

  • Children in whom a serious malformation was found during pregnancy assuming this malformation will lead to very early death or respiratory problems.
  • Serious malformations (ex.anencephalia) will be excluded at birth
  • Other malformations will be estimated by investigator whether it will lead to exclusion.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00322660

Hvidovre University Hospital
Copenhagen, Hvidovre, Denmark, 2650
Hvidovre Hospital
Kettegård Alle 31, Hvidovre, Denmark, 2650
Sponsors and Collaborators
Hvidovre University Hospital
Principal Investigator: Lene A Olsen, M.D. Hvidovre University Hospital, Copenhagen, Kettegaards allé 30, 2650 Hvidovre, DK
Principal Investigator: Pernille Pedersen Hvidovre University Hospital
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00322660     History of Changes
Other Study ID Numbers: 2005091
First Submitted: May 5, 2006
First Posted: May 8, 2006
Last Update Posted: June 28, 2007
Last Verified: June 2007

Additional relevant MeSH terms:
Glucose Metabolism Disorders
Metabolic Diseases
Epinephryl borate
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Vasoconstrictor Agents